Molecular Pharmaceutics
[ASAP] Development of In Silico Models for Predicting Potential Time-Dependent Inhibitors of Cytochrome P450 3A4
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00571
Molecular Pharmaceutics
[ASAP] Telmisartan Nanosuspension for Inhaled Therapy of COVID-19 Lung Disease and Other Respiratory Infections
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00448
Molecular Pharmaceutics
[ASAP] Cyclic and Linear Peptides Containing Alternate WW and RR Residues as Molecular Cargo Delivery Tools
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00664
Molecular Pharmaceutics
[ASAP] Multispecies Machine Learning Predictions of In Vitro Intrinsic Clearance with Uncertainty Quantification Analyses
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00680
Molecular Pharmaceutics
[ASAP] GPIIb/IIIa Receptor Targeted Rutin Loaded Liposomes for Site-Specific Antithrombotic Effect
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00848
Molecular Pharmaceutics
[ASAP] Insight into Heart-Tailored Architectures of Hydrogel to Restore Cardiac Functions after Myocardial Infarction
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00650
Molecular Pharmaceutics
[ASAP] Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00701
Molecular Pharmaceutics
[ASAP] Poly(aspartic acid)-Based Polymeric Nanoparticle for Local and Systemic mRNA Delivery
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00738
Molecular Pharmaceutics
[ASAP] Recent Advancements in the Design of Nanodelivery Systems of siRNA for Cancer Therapy
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00811
Molecular Pharmaceutics
[ASAP] Inactivated Cowpea Mosaic Virus for In Situ Vaccination: Differential Efficacy of Formalin vs UV-Inactivated Formulations
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00744